Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

BACKGROUND: The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to HIV status for patients receiving standard TB therapy in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Pulm Med
Main Authors: Tweed, Conor D., Crook, Angela M., Dawson, Rodney, Diacon, Andreas H., McHugh, Timothy D., Mendel, Carl M., Meredith, Sarah K., Mohapi, Lerato, Murphy, Michael E., Nunn, Andrew J., Phillips, Patrick P. J., Singh, Kasha P., Spigelman, Melvin, Gillespie, Stephen H.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6694514/
https://ncbi.nlm.nih.gov/pubmed/31412895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12890-019-0907-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados